Drug intelligence / Profile preview

ESN282

Development stage: Preclinical
Lead developer: Euroscreen

Overview

ESN282 is an experimental small‑molecule drug program developed by Euroscreen that targets G protein‑coupled receptors implicated in inflammation, and has been described in the context of treating inflammatory diseases such as ulcerative colitis and potentially other immune‑mediated disorders.[15] Publicly available information is limited to high‑level program mentions, with no disclosed clinical‑stage data, specific target identity, chemical class, or detailed mechanism of action, indicating that ESN282 remains an early‑stage discovery or preclinical asset within Euroscreen’s pipeline.[15]

Targets

FFAR2

Beyond the preview

Go deeper on ESN282.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESN282.

Explore the full profile